513 related articles for article (PubMed ID: 10189388)
1. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
[TBL] [Abstract][Full Text] [Related]
2. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
[TBL] [Abstract][Full Text] [Related]
3. [Vancomycin and teicoplanin use as antibiotic prophylaxis in cardiac surgery: pharmacoeconomic study].
Codina C; Miró JM; Tuset M; Claramonte J; Gomar C; Gotsens R; Gómez B; Suárez S; Abellana R; Ascaso C; Cartaña R; Rodríguez E; Asenjo M; Carné X; Trilla A; Marco F; Gómez J; Brunet M; Pomar JL; Gatell JM; Ribas J
Med Clin (Barc); 2000; 114 Suppl 3():54-61. PubMed ID: 10994565
[TBL] [Abstract][Full Text] [Related]
4. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
[TBL] [Abstract][Full Text] [Related]
5. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
6. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
[TBL] [Abstract][Full Text] [Related]
7. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation.
D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F
Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082
[TBL] [Abstract][Full Text] [Related]
8. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
[TBL] [Abstract][Full Text] [Related]
9. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.
Zengin E; Sarper N; Kılıç SC
Pediatr Hematol Oncol; 2011 May; 28(4):311-20. PubMed ID: 21524156
[TBL] [Abstract][Full Text] [Related]
10. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
[TBL] [Abstract][Full Text] [Related]
11. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
[TBL] [Abstract][Full Text] [Related]
12. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
[TBL] [Abstract][Full Text] [Related]
13. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
Corapcioglu F; Sarper N; Zengin E
Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.
Fernández de Gatta MD; Calvo MV; Hernández JM; Caballero D; San Miguel JF; Domínguez-Gil A
Clin Pharmacol Ther; 1996 Sep; 60(3):332-40. PubMed ID: 8841156
[TBL] [Abstract][Full Text] [Related]
15. [Value of the combination of piperacillin and pefloxacin possibly followed by vancomycin in the treatment of febrile neutropenia in nephrotoxic chemotherapy].
Kattan J; Droz JP; Culine S; Ribrag V; Boutan-Laroze A; Andremont A
Bull Cancer; 1992; 79(7):705-12. PubMed ID: 1467596
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
[TBL] [Abstract][Full Text] [Related]
17. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
Kusowska J
Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
[TBL] [Abstract][Full Text] [Related]
18. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
Kusowska J
Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males.
Clay PG; Graham MR; Lindsey CC; Lamp KC; Freeman C; Glaros A
Am J Geriatr Pharmacother; 2004 Sep; 2(3):181-9. PubMed ID: 15561650
[TBL] [Abstract][Full Text] [Related]
20. Piperacillin plus amikacin versus cefotaxime plus amikacin in neutropenic and feverish patients with malignant hemopathies.
Pavone V; Specchia G; Guarini A; Coniglio M; Iaculli L; Girardi F; Colucci A; Liso V
Chemioterapia; 1988 Oct; 7(5):330-5. PubMed ID: 3224402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
